中华肝脏病杂志最新文献

{"title":"[Guidelines for diagnosis and treatment of liver failure (2024 version)].","authors":"","doi":"10.3760/cma.j.cn501113-20241206-00614","DOIUrl":"10.3760/cma.j.cn501113-20241206-00614","url":null,"abstract":"<p><p>Liver failure is a severe clinical syndrome of liver disease with an extremely high mortality rate. Over the years, scholars worldwide have continuously investigated various aspects of liver failure, including its definition, etiology, classification, types, diagnosis and treatment, and prognostic assessment. Based on the latest advances in research, Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association along with Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association have conducted a comprehensive update on the <i>Guidelines for diagnosis and treatment of liver failure (2018 version)</i>. This update aims to offer standardized protocols and evidence-based recommendations to guide the management of liver failure in clinical settings.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"18-33"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on liver fibrosis, cirrhosis, and portal hypertension in 2024].","authors":"S L Xin, X Y Xu","doi":"10.3760/cma.j.cn501113-20241128-00601","DOIUrl":"10.3760/cma.j.cn501113-20241128-00601","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"7-9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver].","authors":"Eda Kaya, Yusuf Yilmaz","doi":"10.3760/cma.j.cn501113-20250103-00003","DOIUrl":"10.3760/cma.j.cn501113-20250103-00003","url":null,"abstract":"<p><p>Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, extrahepatic malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology is cardiovascular disorders, followed by extrahepatic malignancies, diabetes mellitus, and liver-related complications. Furthermore, the severity of extrahepatic diseases is parallel to the severity of NAFLD. In clinical practice, aware-ness of the associations of concomitant diseases is of major importance for initiating prompt and timely screening and multidisciplinary management of the disease spectrum. In 2020, a consensus from 22 countries redefined the disease as metabolic (dysfunction)-associated fatty liver disease (MAFLD), which resulted in the redefinition of the corresponding population. Although the patients diagnosed with MAFLD and NAFLD mostly overlap, the MAFLD and NAFLD populations are not identical. In this review, we compared the associations of key extrahepatic diseases between NAFLD and MAFLD.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"77-87"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Progress in clinical research related to viral hepatitis in 2024].","authors":"Y Ding, Y Li, B C Lu, X G Dou","doi":"10.3760/cma.j.cn501113-20241203-00608","DOIUrl":"10.3760/cma.j.cn501113-20241203-00608","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"3-6"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effects of ascites grading and the application of non-selective beta-blockers on the 1-year prognosis of acute-on-chronic liver failure].","authors":"W S Liu, L J Shen, X He, H Tian, Q H Zhai, D Z Li, S J Xin, S L You","doi":"10.3760/cma.j.cn501113-20240130-00067","DOIUrl":"10.3760/cma.j.cn501113-20240130-00067","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effects of ascites grading and the application of non-selective beta-blockers (NSBBs) on the 1-year prognosis of acute-on-chronic liver failure (ACLF). <b>Methods:</b> 1 386 ascitic cases with ACLF were graded and followed up for one year. The 1-year prognostic effect of ascites grade and NSBBs was analyzed on ACLF by the Kaplan Meier Log-rank test, Cox stepwise regression, and multivariate regression.The <i>t</i>-test, Mann-Whitney <i>U</i>, or Kruskal-Wallis test were used for intergroup comparison of measurement data. The <i>χ</i>² test was used for intergroup comparison of numerical data. <b>Results:</b> The incidence rate of ascites at admission was 77.56% in 1 386 ACLF cases. The Log-rank (Mantel-Cox) of the 1-year survival curve test for 1 386 ACLF patients with ascites grade was 21.384, <i>P</i><0.01. Multivariate regression and Cox stepwise regression analysis showed that ascites grade, age, gastrointestinal bleeding, pulmonary infection, acute kidney injury, prothrombin activity (PTA), urea, MELD-Na score, and the use of NSBBs were closely related to the 1-year prognosis of ACLF. The log rank (Mantel-Cox) of NSBBs treatment in the grade 2/3 ascites group was 6.113, <i>P</i>=0.013, and the difference was statistically significant, suggesting that NSBBs treatment can help improve the 1-year survival rate in ACLF patients with grade 2 and 3 ascites. <b>Conclusions:</b> Ascites grading and the use of NSBBs affect the prognostic factor of ACLF at one year. NSBBs may be beneficial for the long-term prognosis of ACLF, and treatment can be continued in patients who have already received NSBBs prior to the onset of ACLF.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on autoimmune liver disease in 2024].","authors":"L H Zheng, Y Han","doi":"10.3760/cma.j.cn501113-20241214-00620","DOIUrl":"10.3760/cma.j.cn501113-20241214-00620","url":null,"abstract":"<p><p>Autoimmune liver disease (AILD) is a group of chronic inflammatory liver diseases mediated by autoimmune disorders. Early-stage diagnosis and standardized treatment are key to controlling the progression of AILD. Clearing mechanism and exploring new treatment options has always been an important research direction. Herein, the research progress emphasizing the field of AILD in 2024 is reviewed.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"10-12"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress of inherited metabolic liver disease in 2024].","authors":"W Hou, Z P Duan, S J Zheng","doi":"10.3760/cma.j.cn501113-20241202-00606","DOIUrl":"10.3760/cma.j.cn501113-20241202-00606","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"15-17"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Current status and prospects for screening early-stage hepatocellular carcinoma].","authors":"H L Song, S F Jiang, X Yang, X X Yao, C W Pan, P Chen","doi":"10.3760/cma.j.cn501113-20240302-00105","DOIUrl":"10.3760/cma.j.cn501113-20240302-00105","url":null,"abstract":"<p><p>Hepatocellular carcinoma is the most common type of primary liver cancer. Many patients who have been diagnosed with hepatocellular carcinoma are already at an advanced stage, leading to very limited treatment options and poor prognosis. Therefore, the key to improving prognosis is early-stage diagnosis. In recent years, with deeper analysis of the underlying biological mechanisms of HCC, new diagnostic methods have emerged, including emerging serum markers, liquid biopsy, molecular diagnostics, and imaging techniques. This article reviews and analyzes the research progress on early-stage screening and explores their value and application prospects in the early predictive diagnosis of HCC..</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress in the field of liver failure and artificial liver in 2024].","authors":"T Han","doi":"10.3760/cma.j.cn501113-20241204-00611","DOIUrl":"10.3760/cma.j.cn501113-20241204-00611","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"13-14"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety profile of TAF and TDF in vertical transmission of hepatitis B virus].","authors":"Aierkenjiang Malipati, X F Sun, X B Lu","doi":"10.3760/cma.j.cn501113-20240831-00446","DOIUrl":"10.3760/cma.j.cn501113-20240831-00446","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To retrospectively compare the efficacy and safety profile of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) for interrupting mother-to-child transmission of hepatitis B virus (HBV). &lt;b&gt;Methods:&lt;/b&gt; A retrospective study was conducted on 97 cases of HBV-infected pregnant women. Pregnant women were divided into the TDF group (300 mg/d, &lt;i&gt;n&lt;/i&gt;=54) and the TAF group (25 mg/d, &lt;i&gt;n&lt;/i&gt;=43) and were followed up until seven months postpartum. Statistical analysis was analyzed using t-test, analysis of variance, Bonferroni test, Mann-Whitney &lt;i&gt;U&lt;/i&gt; test, or &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test according to different data. &lt;b&gt;Results:&lt;/b&gt; A total of 43 and 54 pregnant women received TAF and TDF treatment. There were 43 and 54 live births, respectively. Both TAF and TDF groups of pregnant women did not discontinue treatment due to adverse events. There was no statistically significant difference in alanine aminotransferase, aspartate aminotransferase, serum creatinine, and uric acid before and after treatment between the two groups. There were no outbreaks of hepatitis during treatment and follow-up among mothers in both groups. The average serum HBV DNA viral load was significantly reduced before and after treatment in both groups, and the difference was statistically significant (TAF: &lt;i&gt;F&lt;/i&gt;=40.33, &lt;i&gt;P&lt;/i&gt;&lt;0.001, TDF: &lt;i&gt;F&lt;/i&gt;=97.77, &lt;i&gt;P&lt;/i&gt;&lt;0.001), but there was no statistically significant difference in the degree of reduction between both groups (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The HBeAg seronegative rates were 0.250, 0.704, and 3.743 at 28 to 32 weeks of gestation, at delivery, and seven months postpartum among pregnant women in both groups, with no statistical significance (&lt;i&gt;P&lt;/i&gt;&gt;0.05). Compared with the TDF, the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in pregnant women in the TAF group at 28 to 32 weeks of gestation and delivery were increased, and the difference between both group was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). Compared with the baseline level, the median LDL-C level increased significantly at seven months postpartum, while the TC, TG, and HDL-C levels returned to normal, and the difference was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). There were no reports of congenital malformations or defects in all newborns at birth. The growth parameters (height, weight, head circumference) of all infants at seven months of age were within the normal range. There was no statistically significant difference between the TAF and TDF groups (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The HBV DNA levels of mothers were significantly lower in both groups than the baseline during the treatment period, and there was no statistically significant difference in the magnitude of reduction between both group (&lt;i&gt;P&lt;/i&gt;&gt;0.05). All infants received HBV immunoprophylaxis, and the MTCT rate was 0. &lt;b&gt;Conclusion:&lt;/b&gt; The use of TAF in the secon","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"31-37"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}